Q-omics provides the consensus-scored MAN1A2 profile across patient tissues and cancer cell-line models. MAN1A2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAN1A2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, MAN1A2 RNA expression shows 20,976 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where MAN1A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAN1A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAN1A2 survival associations across molecular data types. MAN1A2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAN1A2 RNA expression–survival associations across cancer types. High MAN1A2 expression shows unfavorable associations in KICH, LGG, ACC and MESO, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAN1A2 RNA expression.
This table summarizes MAN1A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAN1A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAN1A2 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, LUAD, BLCA and LUSC. The KICH box plot shows higher MAN1A2 RNA expression in normal versus tumor tissue (log2 FC = −1.282, t-test p < 0.001).
This table shows molecular features associated with MAN1A2 in patient tissues and cancer cell lines. In patient samples, MAN1A2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAN1A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
